SCHEMBL4222934

SCHEMBL4222934

COC(=O)C(CCc1ccccc1)CC(=O)c1ccc(-c2ccc(N)cn2)cc1

nearest known ligand 0.48

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.48
HPGDS O60760 1/20 0.40
DPP4 P27487 1/20 0.39
NPC1 O15118 5/20 0.38
RAB9A P51151 4/20 0.38
SMN1; SMN2 Q16637 3/20 0.38
TP53 P04637 1/20 0.38
BAZ2B Q9UIF8 1/20 0.38
FFAR1 O14842 1/20 0.38
MMP2 P08253 1/20 0.37
FAAH O00519 1/20 0.37
F10 P00742 2/20 0.37
LNPEP Q9UIQ6 2/20 0.37
MEN1 O00255 1/20 0.37
F2 P00734 1/20 0.37
PRSS1 P07477 1/20 0.37
NFKB1 P19838 1/20 0.36
NFKB2 Q00653 1/20 0.36
RELA Q04206 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5068496 0.87 KMT2A (0.57) KMT2ADPP4NPC1RAB9ASMN1; SMN2
SCHEMBL1748263 0.87 KMT2A (0.57) KMT2ADPP4NPC1RAB9ASMN1; SMN2
SCHEMBL4221489 0.85 KMT2A (0.52) KMT2ADPP4NPC1RAB9AFAAH
SCHEMBL13752590 0.85 HPGDS (0.39) HPGDSDPP4NPC1RAB9ASMN1; SMN2
SCHEMBL28325731 0.80 KMT2A (0.74) KMT2ADPP4NPC1RAB9ASMN1; SMN2
SCHEMBL28326830 0.78 KMT2A (0.62) KMT2ADPP4NPC1RAB9ASMN1; SMN2
SCHEMBL6031378 0.78 NPC1 (0.58) KMT2ADPP4NPC1RAB9ASMN1; SMN2
SCHEMBL1748086 0.78 NPC1 (0.58) KMT2ADPP4NPC1RAB9ASMN1; SMN2
SCHEMBL4227356 0.75 KMT2A (0.51) KMT2ADPP4NPC1RAB9ASMN1; SMN2
SCHEMBL12313908 0.74 TSHR (0.51) DPP4NPC1RAB9AMMP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090215780-A1 Preparation and Use of Aryl Alkyl Acid Derivatives for the Treatment of Obesity BAYER PHARMACEUTICALS CORPORATION (US) 2009-08-27 US disclosed
US-20090215780-A1 Preparation and Use of Aryl Alkyl Acid Derivatives for the Treatment of Obesity BAYER PHARMACEUTICALS CORPORATION (US) 2009-08-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090215780-A1 Preparation and Use of Aryl Alkyl Acid Derivatives for the Treatment of Obesity FABP4, GPR119, LIPC KMT2A 627/4885HPGDS 1158/4885DPP4 264/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.